Bempedoic Acid and Cardiovascular Outcomes in Statin …
Mar 4, 2023 · The patients were required to provide written confirmation that they were statin intolerant and aware of the benefits of statins in reducing the risk of cardiovascular events, …
Nexletol: Uses, Dosage, Side Effects, Warnings - Drugs.com
Aug 5, 2024 · Nexletol (bempedoic acid) is an oral tablet for high cholesterol that may be used to lower the risk of heart attack and heart procedures (for example stent placement or bypass …
In the cardiovascular outcomes trial [see Clinical Studies (14.1)], 16.4% of NEXLETOL-treated patients experienced clinically significant hyperuricemia reported as an adverse reaction …
U.S. FDA Approves Broad New Labels for NEXLETOL® and …
ANN ARBOR, Mich., March 22, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the United States Food and Drug Administration (FDA) has approved broad …
Nexletol shows CLEAR benefit in cardiovascular outcome trial
4 days ago · New data for Esperion’s cholesterol lowering daily pill Nexletol, used when statins are not working in people at risk of a heart attack, could inject some momentum into the drug’s …
U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® …
Mar 22, 2024 · U.S. FDA approves broad new labels for NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets to prevent heart attacks and …
U.S. FDA Approves Broad New Labels for NEXLETOL® and
Mar 22, 2024 · The U.S. approvals of NEXLIZET and NEXLETOL for cardiovascular risk reduction and LDL-C lowering were based on data generated from the CLEAR Outcomes trial, which …
Statin alternative lowers heart-related deaths - Harvard Health
Oct 1, 2023 · The cholesterol-lowering drug bempedoic acid (Nexletol) can be a good alternative for people who can't take statins. A 2023 study found that compared with a placebo, …
In Brief: Cardiovascular Outcomes with Bempedoic Acid (Nexletol)
CONCLUSION ― In one large clinical trial in statinintolerant patients who had or were at high-risk for cardiovascular disease, the oral adenosine triphosphate- citrate lyase (ACL) inhibitor …
NEXLIZET® & NEXLETOL® HCP Information - Official Site
The most common adverse reactions in the cardiovascular outcomes trial for bempedoic acid, a component of NEXLIZET and NEXLETOL, at an incidence of ≥2% and 0.5% greater than …